We are focused on advancing the development of our lead pipeline assets: sparsentan for FSGS, a serious kidney disorder that often leads to end-stage renal disease;1 and RE-024 for PKAN, a life-threatening neurological disorder that typically begins in early childhood.2learn more
- Middleton, et al. Nephrology Rounds 2007; 5(4).
- Gregory, et al. GeneReviews. 2002.
Retrophin is a biopharmaceutical company focused on discovering, developing and marketing innovative therapies for debilitating and often life-threatening diseases. We are dedicated to working in areas in which the biopharmaceutical industry has, to date, had limited interest or effectiveness. We maintain a focus on patients, working with doctors and patient advocacy groups and seeking to understand their distinct needs.